N115, EmphyCorp‘s investigational non-steroidal nasal spray for the treatment of interstitial lung diseases (ILDs), has completed a Phase 3 clinical trial requested by the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) in patients with pulmonary fibrosis (PF). EmphyCorp’s proprietary…
News
Taking Esbriet (pirfenidone) to manage idiopathic pulmonary fibrosis (IPF) does not increase the risk of heart problems or interfere with commonly used cardiovascular medications, an analysis found. Results of the analysis were published in the journal Advances In Therapy in an article titled, “Cardiovascular Risks,…
People with idiopathic pulmonary fibrosis (IPF) and right heart dysfunction may benefit more from a therapy combining Ofev (nintedanib) with sildenafil than from Ofev alone in terms of cardiac health, according to data from a Phase 3 study. The study, “Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary…
The natural product tannic acid has anti-fibrotic effects on cultured human lung fibroblasts and in an in vivo idiopathic pulmonary fibrosis (IPF) mouse model by reducing signals from TGF-beta receptors, a new study has found. The study, “…
At-home use of wearable physical activity trackers and portable spirometry devices may offer a feasible way of evaluating people with idiopathic pulmonary fibrosis (IPF) taking part in clinical trials, a small study suggests. These findings were reported in “Mobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis,”…
Mutations in two genes, S100A3 and S100A13, were found to be linked to an atypical, early onset form of pulmonary fibrosis (PF) in two families in Saudi Arabia. The newly identified gene variants add to knowledge of the underlying mechanisms of PF development, and further support the involvement of calcium metabolism in…
When idiopathic pulmonary fibrosis (IPF) runs in families, it tends to begin earlier in life and be more severe, a recent study reported. The study,”Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF),” was published in the journal BMC Pulmonary Medicine. As its name…
Only a year ago, Florence Attaway — for decades a half-pack-a-day smoker — struggled to walk even one city block. “I had to take a taxi from my home one block to the hospital because I could hardly breathe,” said the 83-year-old New Yorker, who has chronic obstructive pulmonary…
Note: This is the third article in a series written in collaboration with respiratory therapist Mark W. Mangus Sr., RRT, RPFT, FAARC, and oxygen expert Ryan Diesem. This segment also includes contributions from Donna Frownfelter, PT, DPT, MA, CCS, RRT, FCCP, and Marion Mackles, PT, BS, LMT. The first two…
The mortality rate due to idiopathic pulmonary fibrosis (IPF) increased from 1979 to 2016 in the United Kingdom, a retrospective analysis shows. Researchers estimate that death due to IPF is close to 7% annually among respiratory diseases, pointing to approximately 5,500 people dying from the disease in the U.K.
